Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Studie zu TRE-Versiegelungen bei frühen postoperativen Patienten

9. November 2026 aktualisiert von: Hollister Incorporated

Studie zu TRE-Seals bei frühpostoperativen Patienten

This study will evaluate two Ostomy Seals/Rings in a group of post-operative patients.

Studienübersicht

Status

Rekrutierung

Bedingungen

Studientyp

Interventionell

Einschreibung (Geschätzt)

107

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • County Durham
      • Stockton-on-Tees, County Durham, Vereinigtes Königreich, TS19 8PE
        • Rekrutierung
        • North Tees University Hospital
        • Kontakt:
    • East Sussex
      • Saint Leonards-on-Sea, East Sussex, Vereinigtes Königreich, TN37 7RD
        • Rekrutierung
        • East Sussex Healthcare NHS Trust: Conquest and Eastbourne Hospitals
        • Kontakt:
    • Kent
      • Ashford, Kent, Vereinigtes Königreich, TN24 0LZ
        • Rekrutierung
        • William Harvey Hospital
        • Kontakt:
      • Margate, Kent, Vereinigtes Königreich, CT9 4AN
        • Rekrutierung
        • Queen Elizabeth The Queen Mother Hospital
        • Kontakt:
    • North Yorkshire
      • Middlesbrough, North Yorkshire, Vereinigtes Königreich, TS4 3BW
        • Rekrutierung
        • South Tees University Hospital
        • Kontakt:
    • Surrey
      • Redhill, Surrey, Vereinigtes Königreich, RH1 5RH
        • Rekrutierung
        • East Surrey Hospital
        • Kontakt:
    • West Midlands
      • Coventry, West Midlands, Vereinigtes Königreich, CV2 2DX
        • Rekrutierung
        • University Hospital Coventry
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 85 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. At least 18 years of age
  2. Has their ostomy surgery and post-operative care in the United Kingdom (UK)
  3. Has a colostomy, ileostomy, or urostomy and no reversal planned during the study evaluation period
  4. Able to have first study product applied at first pouch change after surgery (or up to 4 days post-op)
  5. Is appropriate to use a barrier seal per the Investigator
  6. Able to provide an informed consent for study participation
  7. Willing to follow protocol procedures, including participating in study visits, as demonstrated by signing the informed consent

Exclusion Criteria:

  1. Is over 85 years of age
  2. Has received chemotherapy or radiation in the past 30 days or reports beginning chemotherapy or radiation during the study.
  3. A score of 1, 2, or 3 for any of the three OCSI Tool PSC-related domains (i.e., peristomal irritant dermatitis, peristomal bleeding, and hyperplasia) at time of enrollment
  4. Has a fistula in the peristomal area at time of enrollment
  5. Has an open draining wound (not including mucocutaneous separation) in the peristomal area at time of enrollment
  6. Has a suspected infection in the peristomal area at time of enrollment
  7. Is pregnant or lactating at time of enrollment (as determined by interview only)
  8. Is unable to speak, read, and understand English.
  9. Is currently participating in another clinical study using ostomy products
  10. Is currently an employee of Hollister Incorporated or any ostomy manufacturer

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Ein Stomaverschluss

An absorptive ostomy seal

Aktiver Komparator: Ein Stoma-Ring

The Ostomy Ring contains Aloe

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
The Risk of Peristomal Skin Complications (PSCs) as measured using the three PSC-related questions on the Ostomy Complication Severity Index (OCSI)
Zeitfenster: From enrollment to the end of treatment at 9 weeks

The three PSC-related questions on the Ostomy Complication Severity Index (OCSI) are related to peristomal irritant dermatitis, peristomal bleeding, and hyperplasia. Each of these three items is rated on a scale of 0-3, with 0 indicating absence of the condition, and 3 indicating the condition is severe.

From enrollment to the end of treatment at 9 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Total Ostomy Complication Severity Index (OCSI) score and six stomal complication (non-PSC) domains of the OCSI and associated severity
Zeitfenster: From enrollment to the end of treatment at 9 weeks

Each of the OCSI items are scored on a scale of 0-3, with 0 indicating absence of the condition and 3 indicating the condition is severe.

From enrollment to the end of treatment at 9 weeks
Mediation of peristomal skin complications (PSCs) by leakage absorption measured using the leakage item on the Ostomy Complication Severity Index (OCSI)
Zeitfenster: From enrollment to the end of treatment at 9 weeks

The leakage item on the OCSI has a scale of 0 (no leakage) to 3 (leakage approximately 1-2 times per day)

From enrollment to the end of treatment at 9 weeks
Visible moisture/effluent on peristomal skin under the study seal area (OCSI Supplementary Question)
Zeitfenster: From enrollment to the end of treatment at 9 weeks

Assessed only if leakage is reported in the OCSI tool (conditional). Responses: Great amount / Slight amount / None (ordinal categorical).

From enrollment to the end of treatment at 9 weeks
Seal absorption of moisture/effluent under the study seal area (OCSI Supplementary Question)
Zeitfenster: From enrollment to end of treatment at 9 weeks

Participant response to whether the study seal absorbed moisture/effluent from around the stoma/peristomal skin under the seal. Responses: Yes / Somewhat / No, not at all (ordinal categorical).

From enrollment to end of treatment at 9 weeks
Presence of peristomal skin conditions (OCSI Supplementary Question)
Zeitfenster: From enrollment to end of treatment at 9 weeks

Checklist of skin conditions present: burning, itching, maceration, fungal rash, folliculitis, granuloma, mechanical trauma, product sensitivity/allergy, pyoderma gangrenosum, other, none.

From enrollment to end of treatment at 9 weeks
Peristomal skin burning severity (OCSI Supplementary Question)
Zeitfenster: From enrollment to end of treatment at 9 weeks

Rated on a numeric scale from 0 (absent) to 10 (worst burning imaginable). Assessed only if burning is reported (conditional logic from Q25). Higher scores indicate worse burning.

From enrollment to end of treatment at 9 weeks
Peristomal skin itching severity (OCSI Supplementary Question)
Zeitfenster: From enrollment to end of treatment at 9 weeks

Rated on a numeric scale from 0 (absent) to 10 (worst itching imaginable). Assessed only if itching is reported (conditional logic from Q25). Higher scores indicate worse itching.

From enrollment to end of treatment at 9 weeks
Time to resolution of peristomal skin complications (PSCs), assessed by the Ostomy Complication Severity Instrument (OCSI) at visits and adverse event (AE) reports between visits
Zeitfenster: From first PSC onset to resolution through end of treatment at 9 weeks

Unit of Measure: days

From first PSC onset to resolution through end of treatment at 9 weeks
Time to recurrence of peristomal skin complications (PSCs) after resolution, assessed by the OCSI at visits and AE reports between visits
Zeitfenster: From PSC resolution to first recurrence through end of treatment at 9 weeks

Unit of Measure: days

From PSC resolution to first recurrence through end of treatment at 9 weeks
Proportion of participants with PSC occurrence, PSC resolution, and PSC recurrence, assessed by the OCSI at visits and AE reports between visits
Zeitfenster: From enrollment to end of treatment at 9 weeks

Unit of Measure: percent (%)

From enrollment to end of treatment at 9 weeks
Patient satisfaction with the study Seal/Ring assessed using the Study-Specific Patient Satisfaction Questionnaire (Likert scale)
Zeitfenster: From enrollment to the end of treatment at 9 weeks

Rated on a 5-point Likert scale from 1 (Very Satisfied) to 5 (Very dissatisfied)

From enrollment to the end of treatment at 9 weeks
Clinician Satisfaction with the study Seal/Ring assessed using the Study-Specific Clinician Satisfaction Questionnaire (Likert scale)
Zeitfenster: From enrollment to the end of treatment at 9 weeks

Rated on a 5-point Likert scale from 1 (Very Satisfied) to 5 (Very dissatisfied)

From enrollment to the end of treatment at 9 weeks
Ability to correctly use the seal/ring with available instructional resources, assessed by the Study-Specific Instructional Resources Question
Zeitfenster: From enrollment to the end of treatment at 9 weeks

Single study-specific question assessing whether instructional resources (e.g., IFU, online guides) enabled correct use of the seal/ring; responses: Yes / No / Did not use instructional resources. Results will be reported as the proportion of participants in each response category.

From enrollment to the end of treatment at 9 weeks
Seal swelling/expansion incidence, assessed by Study-Specific Swell/Expand Question
Zeitfenster: From enrollment to the end of treatment at 9 weeks

Participant response comparing seal size at application versus at barrier change. Responses: No, seal did not swell/expand / Yes, seal swelled/expanded.

From enrollment to the end of treatment at 9 weeks
Effectiveness of seal swelling/expansion for secure fit against leakage, assessed by Study-Specific Swell/Expand Question
Zeitfenster: From enrollment to end of treatment at 9 weeks

Participant response regarding whether swelling/expansion provided a better, more secure fit against leakage. Responses: No, not at all / Yes, somewhat / Yes, definitely (ordinal categorical).

From enrollment to end of treatment at 9 weeks
Perceived moisture-wicking effect, assessed by the Study-Specific Moisture-Wicking Question (3-point scale)
Zeitfenster: From enrollment to the end of treatment at 9 weeks

Single study-specific question assessing perceived moisture-wicking away from peristomal skin. Responses: No, not at all / Yes, somewhat / Yes, definitely.

From enrollment to the end of treatment at 9 weeks
Clinician agreement with the study Seal/Ring performance assessed using the Study-Specific Clinician Agreement Questionnaire (Likert scale)
Zeitfenster: From enrollment to the end of treatment at 9 weeks

Rated on a 5-point Likert scale from 1 (Strongly agree) to 5 (Strongly disagree)

From enrollment to the end of treatment at 9 weeks
Quantity of seals/rings, barriers, and accessories used, assessed by Study-Specific Resource Utilization Log
Zeitfenster: From enrollment to the end of treatment at 9 weeks

Unit of measure: mean/median number used per participant (counts)

From enrollment to the end of treatment at 9 weeks
Wear/use time (longevity) of seals/rings and barriers, assessed by Study-Specific Resource Utilization Log
Zeitfenster: From enrollment to end of treatment at 9 weeks

Unit of measure: hours or days of wear time per application (time)

From enrollment to end of treatment at 9 weeks
Peristomal skin-related unplanned healthcare visits, assessed by Study-Specific Healthcare Utilization Question
Zeitfenster: From enrollment to end of treatment at 9 weeks

Unit of measure: number of visits per participant; optionally proportion with ≥1 visit (counts/%)

From enrollment to end of treatment at 9 weeks
Total ostomy seal/ring costs, derived from quantities recorded in the Resource and Healthcare Utilization Logs
Zeitfenster: From enrollment to end of treatment at 9 weeks

Unit of measure: currency (e.g., dollars)

From enrollment to end of treatment at 9 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Studienstuhl: John Whitaker, University Hospital Coventry

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

30. Juni 2026

Primärer Abschluss (Geschätzt)

1. März 2027

Studienabschluss (Geschätzt)

1. März 2027

Studienanmeldedaten

Zuerst eingereicht

25. Februar 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

3. März 2026

Zuerst gepostet (Tatsächlich)

10. März 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

12. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

9. November 2026

Zuletzt verifiziert

1. Juli 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 6042-OST

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren